Engineered immune cells take aim at Hard-to-Treat lymphoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: PROCUREMENT Inclusion Criteria: * Referred patients will initially be consented for procurement of blood for generation of the transduced CTL Line. Eligibility criteria at this stage include: * Diagnosis of recurrent HL or NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory HL or NHL with a treatment plan that will include high dose therapy and stem cell transplantation * CD30 positive tumor (can be pending at this time) * EBV seropositivity (can be pending at this time) * Hgb \> 8.0 * Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. TREAMENT Inclusion Criteria: Patients must meet the following eligibility criteria to be included for treatment: * Diagnosis - CD30+ HL or CD30+ NHL * During the dose escalation phase: only adult patients (age 18 and older) with active disease failing standard therapy * After dose escalation: any patient (children or adults) with relapsed CD30+ HL or CD30+ NHL or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and autologous stem cell transplantation. * CD30 positive tumor * EBV seropositivity. * Recovered from acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this study. * Bilirubin 1.5 times or less than upper limit of normal. * AST 3 times or less than upper limit of normal. * Serum creatinine 1.5 times or less than upper limit of normal. * Pulse oximetry of \> 90% on room air * Karnofsky or Lansky score of \> 60%. * Available autologous transduced EBV-specific cytotoxic T lymphocytes with 15% or more expression of CD30CAR determined by flow-cytometry. * Adequate pulmonary function with FEV1, FVC and DLCO 50% or greater of expected corrected for hemoglobin. Exceptions may be allowed for patients with pulmonary involvement after discussing with PI. * Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. * Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form. EXCLUSION CRITERIA: PROCUREMENT Exclusion Criteria: * Active infection with HIV, HTLV, HBV, HCV (can be pending at this time). * Received rituximab within 4 months of blood collection for LCL initiation (unless circulating CD19+ B are =/\>2%) TREATMENT Exclusion Criteria: * Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks. * Received anti-CD30 antibody-based therapy within the previous 6 weeks. * History of hypersensitivity reactions to murine protein-containing products. * Pregnant or lactating. * Tumor in a location where enlargement could cause airway obstruction. * Current use of systemic corticosteroids.